The Montana Cancer Consortium (MCC) consists of three components (two from Billings and one from Great Falls) and three affiliates (Missoula, Helena, and Kalispell). The Consortium encompasses a catchment area which includes the entire state of Montana with extension into Wyoming, Idaho, and the Dakotas (some 150,000 sq. miles/population of 900,000). This area is uniquely rural, as well as home to Native Americans from eight reservations which are served by MCC. The Consortium has a centralized data management office in Billings which serves to register participants and transmit data to the national cooperative groups. The components and affiliates of the MCC have been accruing participants on NCI approved clinical studies for more than 15 years with a current composite total Of 2,010 patients. Objective 1: Accrual. MCC has named the Southwest Oncology Group (SWOG) and the National Surgical Breast and Bowel Project (NSABP) as primary research bases with future addition of Bowman Gray MediCal School for cancer control efforts. First-year therapeutic credits are projected at 110 which represents a 10 % increase in accrual. Cancer control credits for the first year are predicted at 69.9. Objective 2: Quality. MCC centralizes data management for this large geographic area to one office in Billings. Centralization will facilitate registrations and data management for 12 currently participating Montana oncologist (20 total) and expedite the transmittal of data to the research bases. Quality of data submitted to the national groups will be enhanced by quality assurance measures within the central office. Centralized data management will add to the efficiency of quality assessments (i.e. site visits). Objective 3: Access. The cooperative effort of the MCC with hospital and health care providers from Montana and surrounding states will improve access to state-of-the-art cancer treatment and prevention for an extensive, largely rural population. The network of oncologist will provide a higher profile for clinical trials which will create a stimulus to increased accrual. By promoting protocol participation in this geographically unique area with its inclusion of the minority component, MCC provides an excellent site for diffusion of knowledge and improved cancer care in a consortium which embodies the NCI's CCOP intent.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (16))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Montana Cancer Consortium
United States
Zip Code
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440

Showing the most recent 10 out of 151 publications